UCB : A greater impact than anticipated
>Profit warning on 2022 - As announced following the acquisition of Zogenix at end-March, the group has adjusted down its guidance for 2022. However, this adjustment is far greater than anticipated.Indeed, the acquisition of Zogenix followed by its integration has resulted in a -2.5% dilution on the guidance for EBITDA. Fintelpa, approved in March, will only begin to have an accretive effect on EPS as of next year. This impact comes as no surprise and confirms th...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.